• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Vectura awarded $89.7 million in Ellipta patent infringement suit

According to Vectura, a jury has found that US sales of several of GlaxoSmithKline’s Ellipta DPIs infringed on Vectura’s US patent 8303991 (“Method of making particles for use in a pharmaceutical composition”). The jury awarded Vectura $89.7 million in damages and found that GSK willfully infringed on the patent, allowing Vectura to ask for enhanced damages.

Vectura filed suit in the United States District Court for the District of Delaware in July 2016. GSK had informed Vectura at the time that it would not exercise an option for additional patent licenses for Ellipta DPI products after patents expired in 2016 as had been specified under a 2010 agreement. The jury trial began in April 2019 after negotiations between the companies failed, and the verdict came on May 3, 2019.

The damages equate to 3% of US sales of Breo, Anoro, and Incruse Ellipta from August 2016 through December 2018, and Vectura said that it “expects to seek application of the 3% royalty to the sales of the infringing products through the end of the patent term in mid-2021.”

Vectura CEO James Ward-Lilley commented, “Although we regret the need to take a longstanding partner to court, we are pleased with the jury’s verdict which confirms the validity of our intellectual property and the decision to progress this action with GSK. We will provide updates on this matter in due course.”

Read the Vectura press release.

Share

published on May 5, 2019

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews